Corporate Overview

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Compounds derived from Shattuck’s ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead program, SL-172154 (SIRPα-Fc-CD40L), is designed to block the CD47 immune checkpoint and simultaneously activate the CD40 receptor, a member of the tumor necrosis factor superfamily, is being evaluated in Phase 1 clinical trials. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial. Additionally, the company is advancing its second proprietary platform, Gamma Delta T Cell Engagers (GADLEN™), Molecules derived from our GADLEN platform represent a novel approach to targeting gamma delta t-cells and are designed to bridge gamma delta T cells to tumor antigens for the treatment of cancer.

Latest News

View all news

Featured Presentation

Latest Events

View All Events

Latest Quarterly Reports

View All Financial Reports